Exploratory Claims‐Based Assessment of Diagnosed and Potentially Undiagnosed von Willebrand Disease in Japan

This study was conducted in collaboration with Milliman, Inc. Azusa Nagao has received investigator-initiated research/education grant funding from Bayer Yakuhin Ltd., Pfizer Japan Inc., and Chugai Pharmaceutical Co., Ltd.; serves as a medical advisor for Chugai Pharmaceutical Co., Ltd., KM Biologics Co., Ltd., and Novo Nordisk Pharma Ltd.; and has received honoraria from Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Fujimoto Pharmaceutical Corporation, KM Biologics Co., Ltd., Pfizer Japan Inc., Novo Nordisk Pharma Ltd., Sysmex Corporation, Ono Pharmaceutical Co., Ltd., Japan Blood Products Organization, and CSL Behring. Fumikazu Shimamura and Kosuke Iwasaki are employees of Milliman, Inc. The data that support the findings of this study are not publicly available because they were obtained from a commercial health insurance claims database under license. Further information on data availability will be provided upon reasonable request, subject to permission from the database provider.